본문 바로가기
KERD
논문KCI 등재

Preeclampsia and aspirin

황종윤|Tae Gyu Ahn
대한산부인과학회 (Korean Soceity of Obstetrics and Gynecology)|2023.05|Obstetrics & Gynecology Science|제66권 제3호|pp. 120-132|DOI https://doi.org/10.5468/ogs.22261

2

조회

0

다운로드

3

인용

0

참고문헌

키워드

High-risk pregnancyAspirinPreeclampsiaCyclooxygenaseFirst trimester pregnancy
주제분류산부인과학

초록

Preeclampsia (PE) is a multisystem disorder that is an important cause of maternal and perinatal deaths. Currently, delivery is the only final treatment for PE. This practice is usually accompanied by premature birth, which inevitably increases neonatal morbidities. Aspirin is a non-selective non-steroidal anti-inflammatory drug that irreversibly inhibits cyclooxygenase enzymes involved in converting arachidonic acid to prostaglandins and thromboxane. Aspirin inhibits thromboxane A2 production via platelet aggregation, thereby increasing the prostacyclin/thromboxane A2 ratio and reducing platelet aggregation. Since the first case report of aspirin’s potential use during pregnancy was reported in 1978, many studies have attempted to confirm the effect of aspirin on PE, and the results have been controversial. However, this preventive strategy is generally accepted in clinical practice. As evidence for aspirin’s prevention of PE has been accumulating, a recent study investigated the effectiveness of aspirin at high doses of 150 mg, which is higher than before. However, there is an ongoing debate about how much aspirin should be used during pregnancy and when to start aspirin therapy. Guidelines for the use of prophylactic aspirin during pregnancy vary slightly among countries and groups. In this article, we review and summarize the evidence regarding the use of aspirin for PE prevention.

Abstract

Preeclampsia (PE) is a multisystem disorder that is an important cause of maternal and perinatal deaths. Currently, delivery is the only final treatment for PE. This practice is usually accompanied by premature birth, which inevitably increases neonatal morbidities. Aspirin is a non-selective non-steroidal anti-inflammatory drug that irreversibly inhibits cyclooxygenase enzymes involved in converting arachidonic acid to prostaglandins and thromboxane. Aspirin inhibits thromboxane A2 production via platelet aggregation, thereby increasing the prostacyclin/thromboxane A2 ratio and reducing platelet aggregation. Since the first case report of aspirin’s potential use during pregnancy was reported in 1978, many studies have attempted to confirm the effect of aspirin on PE, and the results have been controversial. However, this preventive strategy is generally accepted in clinical practice. As evidence for aspirin’s prevention of PE has been accumulating, a recent study investigated the effectiveness of aspirin at high doses of 150 mg, which is higher than before. However, there is an ongoing debate about how much aspirin should be used during pregnancy and when to start aspirin therapy. Guidelines for the use of prophylactic aspirin during pregnancy vary slightly among countries and groups. In this article, we review and summarize the evidence regarding the use of aspirin for PE prevention.

참고문헌 (81)

  1. Steegers EA, "Pre-eclampsia", Lancet, 376, pp.631~644 (2010)
  2. "Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ task force on hypertension in pregnancy", Obstet Gynecol, 122, pp.1122~1131 (2013)
  3. Irving RJ, "Adult cardiovascular risk factors in premature babies", Lancet, 355, pp.2135~2136 (2000)
  4. Moster D, "Long-term medical and social consequences of preterm birth", N Engl J Med, 359, pp.262~273 (2008)
  5. Wu P, "Preeclampsia and future cardiovascular health : a systematic review and meta-analysis", Circ Cardiovasc Qual Outcomes, 10, pp.e003497~ (2017)
  6. Breetveld NM, "Decreased endothelial function and increased subclinical heart failure in women several years after pre-eclampsia", Ultrasound Obstet Gynecol, 52, pp.196~204 (2018)
  7. "ACOG committee opinion No. 743: low-dose aspirin use during pregnancy", Obstet Gynecol, 132, pp.e44~e52 (2018)
  8. LeFevre ML, "Lowdose aspirin use for the prevention of morbidity and mortality from preeclampsia : US preventive services task force recommendation statement", Ann Intern Med, 161, pp.819~826 (2014)
  9. Askie LM, "Antiplatelet agents for prevention of pre-eclampsia : a meta-analysis of individual patient data", Lancet, 369, pp.1791~1798 (2007)
  10. Staff AC, "Redefining preeclampsia using placenta-derived biomarkers", Hypertension, 61, pp.932~942 (2013)
  11. Phipps EA, "Preeclampsia : pathogenesis, novel diagnostics and therapies", Nat Rev Nephrol, 15, pp.275~289 (2019)
  12. Herraiz I, "Update on the diagnosis and prognosis of preeclampsia with the aid of the sFlt-1", PlGF ratio in singleton pregnancies, 2018, pp.43, 81~89
  13. Walsh SW, "Eicosanoids in preeclampsia", Prostaglandins Leukot Essent Fatty Acids, 70, pp.223~232 (2004)
  14. Walsh SW, "Preeclampsia : an imbalance in placental prostacyclin and thromboxane production", Am J Obstet Gynecol, 152, pp.335~340 (1985)
  15. Moncada S, "Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls", N Engl J Med, 300, pp.1142~1147 (1979)
  16. Mills JL, "Prostacyclin and thromboxane changes predating clinical onset of preeclampsia : a multicenter prospective study", JAMA, 282, pp.356~362 (1999)
  17. Vane JR, "The mechanism of action of aspirin", Thromb Res, 110, pp.255~258 (2003)
  18. Bosetti F, "Arachidonic acid metabolism in brain physiology and pathology : lessons from genetically altered mouse models", J Neurochem, 102, pp.577~586 (2007)
  19. Patrono C, "Aspirin and human platelets : from clinical trials to acetylation of cyclooxygenase and back", Trends Pharmacol Sci, 10, pp.453~458 (1989)
  20. Crofford LJ, "COX-1 and COX-2 tissue expression : implications and predictions", J Rheumatol Suppl, 49, pp.15~19 (1997)
  21. Fitzpatrick FA, "Cyclooxygenase enzymes : regulation and function", Curr Pharm Des, 10, pp.577~588 (2004)
  22. Dubois RN, "Cyclooxygenase in biology and disease", FASEB J, 12, pp.1063~1073 (1998)
  23. Clarke RJ, "Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin", N Engl J Med, 325, pp.1137~1141 (1991)
  24. Lewis PJ, "Prostacyclin in pregnancy", Br Med J, 280, pp.1581~1582 (1980)
  25. Fitzgerald DJ, "Increased thromboxane biosynthesis in normal pregnancy is mainly derived from platelets", Am J Obstet Gynecol, 157, pp.325~330 (1987)
  26. Remuzzi G, "Reduced umbilical and placental vascular prostacyclin in severe pre-eclampsia", Prostaglandins, 20, pp.105~110 (1980)
  27. Fitzgerald DJ, "Decreased prostacyclin biosynthesis preceding the clinical manifestation of pregnancy-induced hypertension", Circulation, 75, pp.956~963 (1987)
  28. Craven LL, "Prevention of coronary and cerebral thrombosis", Miss Valley Med J, 78, pp.213~215 (1956)
  29. Goodlin RC, "Aspirin for the treatment of recurrent toxaemia", Lancet, 2, pp.51~ (1978)
  30. Crandon AJ, "Effect of aspirin on incidence of pre-eclampsia", Lancet, 1, pp.1356~ (1979)
  31. Masotti G, "Differential inhibition of prostacyclin production and platelet aggregation by aspirin", Lancet, 2, pp.1213~1217 (1979)
  32. Bussolino F, "Maternal vascular prostacyclin activity in pre-eclampsia", Lancet, 2, pp.702~ (1980)
  33. Beaufils M, "Prevention of pre-eclampsia by early antiplatelet therapy", Lancet, 1, pp.840~842 (1985)
  34. Uzan S, "Prevention of fetal growth retardation with low-dose aspirin : findings of the EPREDA trial", Lancet, 337, pp.1427~1431 (1991)
  35. CLASP Collaborative Group, "CLASP : a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women", Lancet, 343, pp.619~629 (1994)
  36. Caritis S, "Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units", N Engl J Med, 338, pp.701~705 (1998)
  37. Duley L, "Antiplatelet drugs for prevention of pre-eclampsia and its consequences : systematic review", BMJ, 322, pp.329~333 (2001)
  38. Askie LM, "Antiplatelet agents for prevention of pre-eclampsia : a meta-analysis of individual patient data", Lancet, 369, pp.1791~1798 (2007)
  39. Bujold E, "Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy : a meta-analysis", Obstet Gynecol, 116, pp.402~414 (2010)
  40. Meher S, "Antiplatelet therapy before or after 16 weeks’ gestation for preventing preeclampsia : an individual participant data meta-analysis", Am J Obstet Gynecol, 216, pp.121~128 (2017)
  41. Rolnik DL, "Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia", N Engl J Med, 377, pp.613~622 (2017)
  42. Ayala DE, "Chronotherapy with low-dose aspirin for prevention of complications in pregnancy", Chronobiol Int, 30, pp.260~279 (2013)
  43. "WHO recommendations or prevention and treatment of pre-eclampsia and eclampsia" (2011)[URL]
  44. Lisonkova S, "Incidence of preeclampsia : risk factors and outcomes associated with early-versus lateonset disease", Am J Obstet Gynecol, 209, pp.544~ (2013)
  45. American College of Obstetricians and Gynecologists, "ACOG practice bulletin No. 203 : chronic hypertension in pregnancy", Obstet Gynecol, 133, pp.e26~50 (2019)
  46. Roberge S, "The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction : systematic review and meta-analysis", Am J Obstet Gynecol, 216, pp.110~120 (2017)
  47. Chaemsaithong P, "Does low-dose aspirin initiated before 11weeks' gestation reduce the rate of preeclampsia?", Am J Obstet Gynecol, 222, pp.437~450 (2020)
  48. Roberge S, "Aspirin for the prevention of preterm and term preeclampsia : systematic review and metaanalysis", Am J Obstet Gynecol, 218, pp.287~293 (2018)
  49. Francisco C, "Hidden high rate of pre-eclampsia in twin compared with singleton pregnancy", Ultrasound Obstet Gynecol, 50, pp.88~92 (2017)
  50. Bergeron TS, "Prevention of Preeclampsia with aspirin in multiple gestations : a systematic review and metaanalysis", Am J Perinatol, 33, pp.605~610 (2016)
  51. Euser AG, "Lowdose aspirin for pre-eclampsia prevention in twins with elevated human chorionic gonadotropin", J Perinatol, 36, pp.601~605 (2016)
  52. Kalafat E, "The role of aspirin in prevention of preeclampsia in twin pregnancies : does the dose matter?", Am J Obstet Gynecol, 223, pp.457~458 (2020)
  53. Gent J, "Antenatal management of multiple pregnancies within the UK : a survey of practice", Eur J Obstet Gynecol Reprod Biol, 254, pp.74~78 (2020)
  54. National Collaborating Centre for Women's and Children's Health (UK), "Hypertension in pregnancy: the management of hypertensive disorders during pregnancy" (2010), RCOG Press
  55. Henderson JT, "Aspirin use to prevent preeclampsia and related morbidity and mortality : updated evidence report and systematic review for the US preventive services task force", JAMA, 326, pp.1192~1206 (2021)
  56. O'Gorman N, "Multicenter screening for preeclampsia by maternal factors and biomarkers at 11-13weeks' gestation : comparison with NICE guidelines and ACOG recommendations", Ultrasound Obstet Gynecol, 49, pp.756~760 (2017)
  57. American College of Obstetricians and Gynecologists, "Task force on hypertension in pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ task force on hypertension in pregnancy", Obstet Gynecol, 122, pp.1122~1131 (2013)
  58. Tan MY, "Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers : results of SPREE", Ultrasound Obstet Gynecol, 51, pp.743~750 (2018)
  59. Poon LC, "Early prediction of preeclampsia", Obstet Gynecol Int, 2014, pp.297397~ (2014)
  60. Akolekar R, "Competing risks model in early screening for preeclampsia by biophysical and biochemical markers", Fetal Diagn Ther, 33, pp.8~15 (2013)
  61. Chaemsaithong P, "First trimester preeclampsia screening and prediction", Am J Obstet Gynecol, 226, pp.S1071~97 (2022)
  62. O’Gorman N, "Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation", Am J Obstet Gynecol, 214, pp.103~ (2016)
  63. Rolnik DL, "ASPRE trial : performance of screening for preterm pre-eclampsia", Ultrasound Obstet Gynecol, 50, pp.492~495 (2017)
  64. Tan MY, "Screening for pre-eclampsia by maternal factors and biomarkers at 11-13weeks’ gestation", Ultrasound Obstet Gynecol, 52, pp.186~195 (2018)
  65. Agrawal S, "Metaanalysis and systematic review to assess the role of soluble FMS-like tyrosine kinase-1 and placenta growth factor ratio in prediction of preeclampsia : the SaPPPhirE study", Hypertension, 71, pp.306~316 (2018)
  66. Cerdeira AS, "Angiogenic factors : potential to change clinical practice in pre-eclampsia?", BJOG, 125, pp.1389~1395 (2018)
  67. Bian X, "Short-term prediction of adverse outcomes using the sFlt-1(soluble fms-like tyrosine kinase 1)", PlGF(placental growth factor)ratio in Asian women with suspected preeclampsia, 2019, pp.74, 164~172
  68. Gallo DM, "Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 19-24weeks’ gestation", Am J Obstet Gynecol, 214, pp.619~ (2016)
  69. Litwinska M, "Management of pregnancies after combined screening for pre-eclampsia at 19-24weeks’ gestation", Ultrasound Obstet Gynecol, 52, pp.365~372 (2018)
  70. Hamisu M. Salihu, "Maternal pre-pregnancy underweight and the risk of small-for-gestational-age in Asian-American ethnic groups", Obstetrics & Gynecology Science, 64(6), pp.496~505 (2021), 대한산부인과학회
  71. Pooja Wadhwani, "A study to compare maternal and perinatal outcome in early vs. late onset preeclampsia", Obstetrics & Gynecology Science, 63(3), pp.270~277 (2020), 대한산부인과학회[DOI]
  72. Ebrashy A, "Usefulness of aspirin therapy in high-risk pregnant women with abnormal uterine artery Doppler ultrasound at 14-16weeks pregnancy : randomized controlled clinical trial", Croat Med J, 46, pp.826~831 (2005)
  73. Goffinet F, "ECPPA : randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women", Br J Obstet Gynaecol, 103, pp.719~720 (1996)
  74. Golding J, "A randomised trial of low dose aspirin for primiparae in pregnancy", Br J Obstet Gynaecol, 105, pp.293~299 (1998)
  75. Hermida RC, "Administration time-dependent effects of aspirin in women at differing risk for preeclampsia", Hypertension, 34, pp.1016~1023 (1999)
  76. Michael CA, "Low-dose aspirin in the prevention of pre-eclampsia : current evaluation", Maternal Physiology and Pathology, pp.183~189 (1992)
  77. Morris JM, "A randomized controlled trial of aspirin in patients with abnormal uterine artery blood flow", Obstet Gynecol, 87, pp.74~78 (1996)
  78. Villa PM, "Aspirin in the prevention of pre-eclampsia in high-risk women : a randomised placebo-controlled PREDO trial and a meta-analysis of randomised trials", BJOG, 120, pp.64~74 (2013)
  79. Zhao YM, "Low-dose aspirin prescribed at bed time for the prevention of pre-eclampsia in high-risk pregnant women", Reprod Contracept, 32, pp.355~359 (2012)
  80. Magee LA, "Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy", Pregnancy Hypertens, 4, pp.105~145 (2014)
  81. Lowe SA, "The SOMANZ guidelines for the management of hypertensive disorders of pregnancy 2014", Aust N Z J Obstet Gynaecol, 55, pp.11~16 (2015)

관련 논문AI추천

Hypertensive disorders of pregnancy: advances in understanding and managementLee Ja-Yeon, Lee Sun Hwa대한고혈압학회 · Clinical Hypertension2025 · 제31권 임신성 고혈압환자와 혈중 Thromboxane 농도김소정, 윤병일, 이경민, 이규창, 이창훈, 정두용대한산부인과학회 · Obstetrics & Gynecology Science2004 · 제47권 제9호국내 산과 전문의의 임신 중 고혈압성 질환 임상진료패턴 분석김석영, 김수미, 김연희, 김윤숙, 신재은, 안태규, 오영림, 이민아, 이순애, 황종윤, 이귀세라한국모자보건학회 · 한국모자보건학회지2021 · 제25권 제3호A study to compare maternal and perinatal outcome in early vs. late onset preeclampsiaJaswinder Kaur Kalra, Pooja Wadhwani, Pradip Kumar Saha, Shalini Gainder, Venkataseshan Sundaram대한산부인과학회 · Obstetrics & Gynecology Science2020 · 제63권 제3호Hydroxychloroquine in obstetrics: potential implications of the prophylactic use of hydroxychloroquine for placental insufficiency during pregnancyHyun-Hwa Cha, Ji-Hee Sung, Soo-Young Oh, Yoo-Min Kim대한산부인과학회 · Obstetrics & Gynecology Science2024 · 제67권 제2호Evaluation of sFlt-1/PlGF Ratio for Predicting and Improving Clinical Management of Pre-eclampsia: Experience in a Specialized Perinatal Care CenterCécile Tardif, Damien Masson, Erwan Dumontet, Hélène Caillon, Norbert Winer대한진단검사의학회 · Annals of Laboratory Medicine2018 · 제38권 제2호

이 간행물의 다른 논문 (12건)

The red line initiative: women as weapons as warJeanne A Conrypp. 119-119Diagnostic imaging of adnexal masses in pregnancyJihye Lim, Jeong-Won Sohn, Maria Lee, Seung Mi Lee, Junhwan Kimpp. 133-148Pregnancy and COVID-19: past, present and future김의혁, 김영근pp. 149-160Frequency of third trimester umbilical artery Doppler for improving neonatal outcomes in high-risk pregnancies: a randomized trialHanan Hanna Rizk, Mohamed Hamed Salama, Maii Nawarapp. 161-168The introduction to air pollution on pregnancy outcome (APPO) study: a multicenter cohort studyYoung-Ah You, Gain Lee, Geum Joon Cho, Min-Jeong Oh, Young Min Hur, AbuZar Ansari, Kyung A Lee, Yeon-Sung Jung, Sung Hun Na, Tae Gyu An, Yu-Hwan Kim, Soo-Jeong Lee, Na Kyung Kim, 박미혜, Se Jin Lee, Jin-Gon Bae, Soo Min Kim, 하은희, Eunjin Kwon, 김영한, Soo Jung Kim, Young Ju Kim, Sunwha Parkpp. 169-180
원문 보기